Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma

Abstract

Vaccination against influenza and Streptococcus pneumoniae is recommended for elderly and immunocompromised individuals. However, there is little information concerning the efficacy of vaccination in specific groups of patients. In this study, 52 patients underwent vaccination against influenza, S. pneumoniae and Haemophilus influenzae type b (Hib) as they attended hospital outpatient clinics. Serum was analysed prior to vaccination and 4-6 weeks afterwards. Antibody titres against S. pneumoniae and Hib were compared with reference values corresponding to the geometric mean titres of a healthy UK population. For influenza vaccination, haemagglutination inhibition (HI) titres were measured against three inactivated strains; a titre of > or = 1/40 was considered protective. No patient had protective titres to all three antigens prior to vaccination and 41 patients (85%) had titres < 1/40 to all 3 strains. Post vaccination only 9/48 patients (19%) achieved protective antibody titres. Resistance to S. pneumoniae and response to Pneumovax II was also poor: prevaccination, 45 patients (93%) had suboptimal antibody titres and in 26/43 patients (61%) titres remained low post vaccination. Resistance to Hib and response to vaccination was comparable with the healthy adult UK population. These results question the practice of routine influenza and pneumococcal vaccination in myeloma patients.

References 25

1. 1.

   Admon D., Engelhard D., Strauss N., Goldman N., Zakay-Rones Z. Antibody response to influenza immunization in patients after heart transplantation. Vaccine. 1997;15(14):1518-1522.

   Not in our library10.1016/s0264-410x(97)00193-x

2. 2.

   Ahmed A. E., Nicholson K. G., Nguyen-Van-Tam J. S. Reduction in mortality associated with influenza vaccine during 1989-90 epidemic. Lancet. 1995;346(8975):591-595.

   Not in our library10.1016/s0140-6736(95)91434-x

3. 3.

   Anderson H., Petrie K., Berrisford C., Charlett A., Thatcher N., Zambon M. Seroconversion after influenza vaccination in patients with lung cancer. Br J Cancer. 1999;80(1-2):219-220.

   Not in our library10.1038/sj.bjc.6690342

4. 4.

   Brydak L. B., Rokicka-Milewska R., Machała M., Jackowska T., Sikorska-Fic B. Immunogenicity of subunit trivalent influenza vaccine in children with acute lymphoblastic leukemia. Pediatr Infect Dis J. 1998;17(2):125-129.

   Not in our library10.1097/00006454-199802000-00009

5. 5.

   Chakraverty P. Antigenic relationship between influenza B viruses. Bull World Health Organ. 1971;45(6):755-766.

   Not in our library

6. 6.

   Dedman D. J., Zambon M., Buynder P. V., Fleming D. M., Watson J. M., Joseph C. A. Influenza surveillance in England and Wales: October 1997 to June 1998. Commun Dis Public Health. 1998;1(4):244-251.

   Not in our library

7. 7.

   Deresinski S. C., Stevens D. A. Disseminated herpes simplex in untreated multiple myeloma. Paradox of present concepts of immune defects. Oncology. 1974;30(4):318-323.

   Not in our library10.1159/000224970

8. 8.

   FAHEY J. L., SCOGGINS R., UTZ J. P., SZWED C. F. INFECTION, ANTIBODY RESPONSE AND GAMMA GLOBULIN COMPONENTS IN MULTIPLE MYELOMA AND MACROGLOBULINEMIA. Am J Med. 1963;35:698-707.

   Not in our library10.1016/0002-9343(63)90140-2

9. 9.

   Gribabis D. A., Panayiotidis P., Boussiotis V. A., Hannoun C., Pangalis G. A. Influenza virus vaccine in B-cell chronic lymphocytic leukaemia patients. Acta Haematol. 1994;91(3):115-118.

   Not in our library10.1159/000204315

10. 10.

    Gross P. A., Quinnan G. V., Weksler M. E., Setia U., Douglas R. G. Relation of chronic disease and immune response to influenza vaccine in the elderly. Vaccine. 1989;7(4):303-308.

    Not in our library10.1016/0264-410x(89)90190-4

11. 11.

    Hobson D., Curry R. L., Beare A. S., Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond). 1972;70(4):767-777.

    Not in our library10.1017/s0022172400022610

12. 12.

    Honkanen P. O., Keistinen T., Kivelä S. L. Reactions following administration of influenza vaccine alone or with pneumococcal vaccine to the elderly. Arch Intern Med. 1996;156(2):205-208.

    Not in our library

13. 13.

    Iorio A. M., Alatri A., Francisci D., Preziosi R., Neri M., Donatelli I., Castrucci M. R., Biasio L. R., Tascini C., Iapoce R. Immunogenicity of influenza vaccine (1993-94 winter season) in HIV-seropositive and -seronegative ex-intravenous drug users. Vaccine. 1997;15(1):97-102.

    Not in our library10.1016/s0264-410x(96)00057-6

14. 14.

    Jackson L. A., Benson P., Sneller V. P., Butler J. C., Thompson R. S., Chen R. T., Lewis L. S., Carlone G., DeStefano F., Holder P. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA. 1999;281(3):243-248.

    Not in our library10.1001/jama.281.3.243

15. 15.

    Luque R., Brieva J. A., Moreno A., Manzanal A., Escribano L., Villarrubia J., Velasco J. L., López-Jiménez J., Cerveró C., Otero M. J. Normal and clonal B lineage cells can be distinguished by their differential expression of B cell antigens and adhesion molecules in peripheral blood from multiple myeloma (MM) patients--diagnostic and clinical implications. Clin Exp Immunol. 1998;112(3):410-418.

    Not in our library10.1046/j.1365-2249.1998.00600.x

16. 16.

    Lyall E. G., Charlett A., Watkins P., Zambon M. Response to influenza virus vaccination in vertical HIV infection. Arch Dis Child. 1997;76(3):215-218.

    Not in our library10.1136/adc.76.3.215

17. 17.

    Miotti P. G., Nelson K. E., Dallabetta G. A., Farzadegan H., Margolick J., Clements M. L. The influence of HIV infection on antibody responses to a two-dose regimen of influenza vaccine. JAMA. 1989;262(6):779-783.

    Not in our library

18. 18.

    Musto P., Carotenuto M. Vaccination against influenza in multiple myeloma. Br J Haematol. 1997;97(2):505-506.

    Not in our library

19. 19.

    Norden C. W. Infections in patients with multiple myeloma. Arch Intern Med. 1980;140(9):1150-1151.

    Not in our library

20. 20.

    Parkkali T., Käyhty H., Ruutu T., Volin L., Eskola J., Ruutu P. A comparison of early and late vaccination with Haemophilus influenzae type b conjugate and pneumococcal polysaccharide vaccines after allogeneic BMT. Bone Marrow Transplant. 1996;18(5):961-967.

    Not in our library

21. 21.

    Ringdén O. Allogeneic bone marrow transplantation for hematological malignancies--controversies and recent advances. Acta Oncol. 1997;36(6):549-564.

    Not in our library10.3109/02841869709001316

22. 22.

    Savage D. G., Lindenbaum J., Garrett T. J. Biphasic pattern of bacterial infection in multiple myeloma. Ann Intern Med. 1982;96(1):47-50.

    Not in our library10.7326/0003-4819-96-1-47

23. 23.

    Sullivan K. M., Monto A. S., Foster D. A. Antibody response to inactivated influenza vaccines of various antigenic concentrations. J Infect Dis. 1990;161(2):333-335.

    Not in our library10.1093/infdis/161.2.333

24. 24.

    Vladutiu A. O. The severe combined immunodeficient (SCID) mouse as a model for the study of autoimmune diseases. Clin Exp Immunol. 1993;93(1):1-8.

    Not in our library10.1111/j.1365-2249.1993.tb06488.x

25. 25.

    Zuckerman M. A., Wood J., Chakraverty P., Taylor J., Heath A. B., Oxford J. S. Serological responses in volunteers to inactivated trivalent subunit influenza vaccine: antibody reactivity with epidemic influenza A and B strains and evidence of a rapid immune response. J Med Virol. 1991;33(2):133-137.

    Not in our library10.1002/jmv.1890330213

Cited by papers we hold 1

• Epidemiology of invasive pneumococcal infections: manifestations, incidence and case fatality rate correlated to age, gender and risk factors · 2016
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.